{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:08Z","timestamp":1786998368057,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100031160","name":"Cartesian Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ymthe.2026.04.008","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:51:03Z","timestamp":1776801063000},"page":"2561-2563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Descartes-08: Unlocking the potential of mRNA CAR T-cell therapy in myasthenia gravis"],"prefix":"10.1016","volume":"34","author":[{"suffix":"Jr.","given":"James F.","family":"Howard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.04.008_bib1","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.008_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado2084","article-title":"Engineering CAR-T therapies for autoimmune disease and beyond","volume":"16","author":"English","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.04.008_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686466","article-title":"Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders","volume":"12","author":"Zografou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.008_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nmd.2019.12.003","article-title":"Emerging therapies for autoimmune myasthenia gravis: towards treatment without corticosteroids","volume":"30","author":"Tannemaat","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2026.04.008_bib5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymthe.2026.04.008_bib6","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/acn3.70167","article-title":"Durability of response to B-cell maturation antigen-directed mRNA cell therapy in myasthenia gravis","volume":"12","author":"Chahin","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2026.04.008_bib7","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","article-title":"BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"32","author":"Vu","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.04.008_bib8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2026.04.008_bib9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/s41591-025-04170-z","article-title":"BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial","volume":"32","author":"Fedak","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.04.008_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600273X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162600273X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:35:27Z","timestamp":1781829327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162600273X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S152500162600273X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.04.008","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Descartes-08: Unlocking the potential of mRNA CAR T-cell therapy in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}